{"nctId":"NCT00234832","briefTitle":"A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients","startDateStruct":{"date":"2003-01"},"conditions":["Obesity"],"count":10777,"armGroups":[{"label":"Sibutramine","type":"EXPERIMENTAL","interventionNames":["Drug: Sibutramine hydrochloride"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Lead-in sibutramine","type":"EXPERIMENTAL","interventionNames":["Drug: Sibutramine hydrochloride"]}],"interventions":[{"name":"Sibutramine hydrochloride","otherNames":["ABT-991","sibutramine","Meridia","Reductil"]},{"name":"Placebo","otherNames":[]},{"name":"Sibutramine hydrochloride","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject's body mass index (BMI) was \\>= 27 kg/m(2) and \\<= 45 kg/m(2) or their BMI was \\>= 25 kg/m(2) and \\< 27 kg/m(2) with waist circumference of \\>= 102 cm in males or \\>= 88 cm in females.\n* Medical history positive for:\n\n  * Preexisting cardiovascular disease (i.e., coronary artery disease, cerebrovascular disease, or peripheral arterial occlusive disease) and/or\n  * Type 2 diabetes mellitus with at least 1 other risk factor (i.e., dyslipidemia, controlled hypertension, current smoker, or diabetic nephropathy with evidence of microalbuminuria)\n\nExclusion Criteria:\n\n* History of recent myocardial infarction.\n* Heart failure symptoms greater than New York Heart Association Functional Class II.\n* Hemodynamically significant valvular or left ventricular (LV) tract obstruction.\n* Subjects without a pacemaker and with any of the following:\n\n  * Sinus bradycardia (\\< 50 bpm)\n  * Sick sinus syndrome\n  * Atrioventricular block of more than 1st degree\n* Mean sitting systolic blood pressure (SBP) \\> 160 mmHg. Mean sitting diastolic blood pressure (DBP) \\> 100 mmHg. Mean sitting heart rate (HR) \\> 100 bpm.\n* Syncopal episodes presumed to be due to uncontrolled life-threatening arrhythmias.\n* Planned cardiac surgery or coronary angioplasty within 6 months of screening.\n* History of recent non-hemorrhagic stroke or transient ischemic attack (TIA), history of hemorrhagic stroke.\n* Hyperthyroidism.\n* Known chronic liver disease or endstage renal disease.\n* Severe, symptomatic benign prostatic hyperplasia which may require surgery.\n* Known pheochromocytoma, history of narrow angle glaucoma, Gilles de la Tourette syndrome, history of seizures, history of bariatric or abdominal obesity surgery (excluding liposuction).\n* Concomitant use of monoamine oxidase inhibitors or drugs that increase levels of serotonin in the brain.\n* Treated hypertension stabilized for less than 3 months.\n* Inability to perform regular physical activity.","healthyVolunteers":false,"sex":"ALL","minimumAge":"55 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Risk of Experiencing a Primary Outcome Event (POE) (i.e., Nonfatal Myocardial Infarction [MI], Nonfatal Stroke, Resuscitated Cardiac Arrest, Cardiovascular [CV] Death)","description":"For each subject, POE status (with/without an event) and time to first occurrence of a POE using time-to-event analysis were evaluated. All POE confirmed by an independent adjudication committee were included in the analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"561","spread":null},{"groupId":"OG001","value":"490","spread":null},{"groupId":"OG002","value":"79","spread":null},{"groupId":"OG003","value":"77","spread":null},{"groupId":"OG004","value":"77","spread":null},{"groupId":"OG005","value":"66","spread":null},{"groupId":"OG006","value":"403","spread":null},{"groupId":"OG007","value":"346","spread":null}]}]}]},{"type":"SECONDARY","title":"Risk of Death From Any Cause (All-cause Mortality)","description":"For each subject who died, the time to death was evaluated using time-to-event analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"418","spread":null},{"groupId":"OG001","value":"404","spread":null}]}]}]},{"type":"SECONDARY","title":"Risk of Experiencing a POE or a Revascularization Procedure","description":"This outcome includes nonfatal MI, nonfatal stroke, resuscitated cardiac arrest, CV death (including events such as fatal MI and fatal stroke), and any of the following revascularization procedures: percutaneous transluminal coronary angioplasty, coronary artery bypass graft, coronary artery stent placement, cardiac transplant, peripheral vascular bypass or angioplasty, and carotid endarterectomy. For each subject, the POE or revascularization status (yes/no) and time to first occurrence of an event using time-to-event analysis were evaluated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"927","spread":null},{"groupId":"OG001","value":"856","spread":null}]}]}]},{"type":"SECONDARY","title":"Risk of Experiencing a Nonfatal MI Included in the POE","description":"For each subject, the first occurrence of a nonfatal MI included in the POE was evaluated using time-to-event analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"200","spread":null},{"groupId":"OG001","value":"159","spread":null}]}]}]},{"type":"SECONDARY","title":"Risk of Experiencing a Nonfatal Stroke Included in the POE","description":"For each subject, the time to first occurrence of a nonfatal stroke included in the POE was evaluated using time-to-event analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"95","spread":null}]}]}]},{"type":"SECONDARY","title":"Risk of Experiencing a Resuscitated Cardiac Arrest Included in the POE","description":"For each subject, the time to first occurrence of a resuscitated cardiac arrest included in the POE was evaluated using time-to-event analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Risk of Experiencing Cardiovascular Death Included in the POE","description":"For each subject, the time to cardiovascular death included in the POE was evaluated using time-to-event analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"223","spread":null},{"groupId":"OG001","value":"229","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":425,"n":10744},"commonTop":[]}}}